For the Inventor, By the Inventor

Enter assignee name

Bellinzona, Switzerland

Institute for Research in Biomedicine

USPTO Granted Patents = 56

CIPO Patents = 5

EPO Patents = 34

Forward Citations = 360

Loading Chart...

Loading Chart...

67 inventors (with patents filed for the assignee):

Antonio Lanzavecchia (50 out of 64 patents)

Annalisa Macagno (25 out of 38 patents)

Davide Corti (13 out of 50 patents)

4. Baoshan Zhang (8 out of 30 patents)

5. Guillaume Stewart-Jones (7 out of 17 patents)

6. Yongping Yang (6 out of 25 patents)

7. Peter D Kwong (5 out of 51 patents)

8. Ursula J Buchholz (4 out of 31 patents)

9. Peter L Collins (4 out of 62 patents)

10. Michael Gordon Joyce (4 out of 27 patents)

11. David Baker (3 out of 68 patents)

12. Gwo-Yu Chuang (3 out of 17 patents)

13. Neil P King (3 out of 17 patents)

14. Lance Joseph Stewart (3 out of 13 patents)

15. Laurent Perez (3 out of 3 patents)

Core Competencies:

Prefusion Immunogens

Malaria Vaccines

Neutralizing Antibodies

Self-Assembling Nanostructures

Recombinant Proteins

CXCL12/HMGB1 Interaction

T Cell Modulators

Monoclonal Antibody Production

Ebola Virus Antibodies

Dengue Virus Antibodies

Human Cytomegalovirus

Influenza A Virus Antibodies

56 patents: Sort by Forward Citations

1. 12435113 - Prefusion PIV F immunogens and their use (2025-10-07),

2. 12383609 - Plasmodium sporozoite NPDP peptides as vaccine and target novel malaria vaccines and antibodies binding to (2025-08-12),

3. 12331108 - Antibodies with functional domains in the elbow region between variable and constant domain (2025-06-17),

4. 12297258 - Antibodies againstspecies (2025-05-13),

5. 12275757 - Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use (2025-04-14),

6. 12233124 - Recombinant metapneumovirus f proteins and their use (2025-02-25),

7. 12098175 - Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof (2024-09-24),

8. 11845778 - Prefusion PIV F immunogens and their use (2023-12-19),

9. 11839651 - Immunogenic compositions and uses thereof (2023-12-12),

10. 11786591 - Recombinant metapneumovirus F proteins and their use (2023-10-17),

11. 11732011 - Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use (2023-08-22),

12. 11261245 - Ultra-potent neutralization of GM-CSF by multispecific antibodies and uses thereof (2022-03-01),

13. 11192926 - Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use (2021-12-07),

14. 11167015 - Arginine and its use as a T cell modulator (2021-11-09),

15. 11084850 - Recombinant prefusion RSV F proteins and uses thereof (2021-08-10),

The Institute for Research in Biomedicine (IRB Barcelona) is a world-leading research centre focused on understanding fundamental questions about human health and diseases. Their multidisciplinary research teams work at the interface of biology, chemistry, and computer science to unravel the complexities of biological systems. Through cutting-edge research and innovation, IRB Barcelona strives to advance knowledge, contribute to medical breakthroughs, and ultimately improve human health.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

56 Patents

#1 in Bellinzona

#253 in Switzerland

#12,434 in the World

Bellinzona, Switzerland

Institute for Research in Biomedicine

Forward Citations = 360

67 inventors:

Antonio Lanzavecchia (50 out of 64 patents)

Annalisa Macagno (25 out of 38 patents)

Davide Corti (13 out of 50 patents)

4. Baoshan Zhang (8 out of 30 patents)

5. Guillaume Stewart-Jones (7 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…